secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-06-23T11:10:57+00:00
Accession:  0001104659-26-076627
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma receives $2.5M additional DoD funding for AP-SA02 Phase 3 readiness
--------------------------------------------------------------------------------

- Received $2.5M additional non-dilutive funding from U.S. DoD; total DoD award now $28.7M for AP-SA02 development.
- Funding supports Phase 3 readiness of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia.
- Company plans to initiate Phase 3 superiority study of AP-SA02 in H2 2026.
- DoD funding provided via MTEC and managed by NMRC/NAMD; non-dilutive nature preserves shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/0001104659-26-076627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/tm2618503d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer